|
A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer Clinical research trials and A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer. A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer clinical trial. Human subjects often receive the most effective healthcare possible for their A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer  A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer
A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer
For Condition: Carcinoma, Non-Small-Cell Lung,Pancreatic Neoplasms,Colorectal Neoplasms,Breast Neoplasms
Status: Completed
Sponsor(s): Pfizer ,
Synopsis: CI-1040 is an experimental drug that is being tested in patients who have advanced colorectal and lung cancer who failed no more than one prior chemotherapy regimen, breast cancer who have failed no more than 2 prior regimens and in patients with pancreatic cancer who have received no prior chemotherapy. CI-1040 is taken orally twice daily with meals. Patients are required to have blood tests periodically while receiving treatment and will be monitored closely throughout the trial for possible side effects and for response.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Patients who are at least 18 years or older who have pathological or histological confirmation of colorectal, nonsmall-cell lung, breast or pancreas cancer. - No more than 1 prior chemo for lung or colon cancer, no more than 2 for breast and no prior chemotherapy for pancreas cancer. - Original or recent tumor tissue must be available. - Patients must have been off prior chemotherapy for 4 weeks and radiation for 3 weeks. - Patients must have adequate renal, liver and bone marrow function, not have serious infection or life-threatening illness (unrelated to tumor). - Must be able to swallow capsules and not have gastrointestinal disorders that may affect absorption of the drug.
Total Enrollment: 172
Location and Contact Information:
Cedars-Sinai Comprehensive Cancer Center
Los Angeles, California, 90048-1804
United States
263 Wallace Tumor Institute
Birmingham, Alabama, 35294
United States
Mayo Clinic
Rochester, Minnesota, 55905
United States
Oncology Hematology Care, Inc
Cincinnati, Ohio, 45236
United States
UCLA School of Medicine
Los Angeles, California, 90095
United States
Harper Hospital
Detroit, Michigan, 48201
United States
Additional Information:
Study ID Numbers: 1040-000-002;
Study Start Date:
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034827
Other Colorectal Neoplasms Studies:
1. Trial of Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer in Previously Treated Patients
2. A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin versus Gemcitabine and Cisplatin in Patients with Advanced, Previously Untreated Non-Small Cell Lung Cancer
3. Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC)
4. Study of Temozolomide in the Treatment of Brain Metastasis from Non-small-cell Lung Cancer
5. A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer
Related Studies:
Other Colorectal Neoplasms Clinical Trials
Other Minnesota Clinical Trials
Other Rochester Clinical Trials
A multicenter phase 2 study of CI-1040 in patients with advanced nonsmall-cell lung cancer, breast cancer, colon cancer, or pancreatic cancer
|
|
|
|
|
|
|
|
